Clinical Trials

Inclusion Criteria:

- Patients admitted to Mayo Clinic/Jacksonville, post-stroke with a hemiparetic upper extremity.

- Able to provide consent of participation by self-agreement.

- Patients with a hemiparetic upper extremity will be determined using the NIH Motor Arm subsection from the NIH scale and score a 1-4.

- Patients who have received thrombolytic therapeutic medicine > 13 hours (per site specific policy) will not be excluded from inclusion in this study.

- Patients who score > 13 on the BIMS to ensure intact cognition.

Exclusion Criteria:

- Inability to provide consent of participation.

- Subjects with aphasia or the inability to effectively communicate their pain consistently.

- Questionable reliability scoring < 13 on the BIMS, has an existing invasive line (PICC line, IV, AV fistula or AV graft); recent surgery or vein ligation in the involved
extremity.

- Recent skin graft in the involved extremity.

- Confirmed DVT in the affected.

- Upper extremity including axillary or subclavian veins; open or active wounds or infection in the involved extremity.

- Upper extremity ischemia, gangrene, cellulitis or severe arteriosclerosis in the affected upper extremity.

- Status-post axillary lymph node dissection on the involved side; congestive heart failure (CHF) acute exacerbation; acute edema of unknown etiology in the involved
upper extremity.

- Subjects with extreme deformity of the affected upper extremity.

- Subjects with an acute kidney injury.

- Subjects who are hemodynamically unstable 1,7,17.

- Patients who have received thrombolytic therapeutic medicine administered < 13 hours (per site specific policy) prior to application of SCD sleeve.